Towards optimising the provision of laboratory services for bone turnover markers

Samuel Vasikaran, Paul Chubb, H.G. Schneider

    Research output: Contribution to journalReview article

    7 Citations (Scopus)

    Abstract

    Bone turnover markers (BTMs) are either secreted by osteoblasts during bone formation or released by degradation of the collagen matrix of bone during bone resorption, and may be measured in blood or urine to provide an estimate of the rate of bone remodelling. Increased bone remodelling rate is often associated with bone loss which can result in osteoporosis; however, lack of data preclude the inclusion of BTMs in fracture risk algorithms. The changes in BTMs following therapy for osteoporosis may be useful for monitoring. Serum procollagen type I amino-terminal propeptide (s-PINP) and serum carboxy-terminal cross-linking telopeptide of type I collagen (s-βCTX) have been designated as reference standard markers of bone formation and resorption respectively in osteoporosis; further research is needed for their routine use in osteoporosis. BTMs are useful in diagnosing and monitoring Paget's disease of bone and other bone diseases associated with abnormal bone formation and/or resorption. Standardised patient preparation is required to mitigate the effect of biological variation, and appropriate sample handling and storage are important to minimise sample degradation. Significant inter-method differences exist for BTMs, and harmonisation of methods for the reference BTMs is being pursued. This will help develop universally accepted decision limits and treatment goals. Australian consensus reference intervals have been developed for some methods for s-PINP and s-βCTX © 2014 Royal College of Pathologists of Australasia.
    Original languageEnglish
    Pages (from-to)267-273
    JournalPathology
    Volume46
    Issue number4
    DOIs
    Publication statusPublished - 2014

    Fingerprint

    Bone Remodeling
    Osteoporosis
    Bone Resorption
    Osteogenesis
    Collagen Type I
    Bone and Bones
    Australasia
    Osteitis Deformans
    Bone Diseases
    Serum
    Osteoblasts
    Collagen
    Urine
    Therapeutics
    Research

    Cite this

    Vasikaran, Samuel ; Chubb, Paul ; Schneider, H.G. / Towards optimising the provision of laboratory services for bone turnover markers. In: Pathology. 2014 ; Vol. 46, No. 4. pp. 267-273.
    @article{9df868ef8b164f85845db324aaeea18f,
    title = "Towards optimising the provision of laboratory services for bone turnover markers",
    abstract = "Bone turnover markers (BTMs) are either secreted by osteoblasts during bone formation or released by degradation of the collagen matrix of bone during bone resorption, and may be measured in blood or urine to provide an estimate of the rate of bone remodelling. Increased bone remodelling rate is often associated with bone loss which can result in osteoporosis; however, lack of data preclude the inclusion of BTMs in fracture risk algorithms. The changes in BTMs following therapy for osteoporosis may be useful for monitoring. Serum procollagen type I amino-terminal propeptide (s-PINP) and serum carboxy-terminal cross-linking telopeptide of type I collagen (s-βCTX) have been designated as reference standard markers of bone formation and resorption respectively in osteoporosis; further research is needed for their routine use in osteoporosis. BTMs are useful in diagnosing and monitoring Paget's disease of bone and other bone diseases associated with abnormal bone formation and/or resorption. Standardised patient preparation is required to mitigate the effect of biological variation, and appropriate sample handling and storage are important to minimise sample degradation. Significant inter-method differences exist for BTMs, and harmonisation of methods for the reference BTMs is being pursued. This will help develop universally accepted decision limits and treatment goals. Australian consensus reference intervals have been developed for some methods for s-PINP and s-βCTX {\circledC} 2014 Royal College of Pathologists of Australasia.",
    author = "Samuel Vasikaran and Paul Chubb and H.G. Schneider",
    year = "2014",
    doi = "10.1097/PAT.0000000000000092",
    language = "English",
    volume = "46",
    pages = "267--273",
    journal = "Pathology",
    issn = "0031-3025",
    publisher = "Pergamon",
    number = "4",

    }

    Towards optimising the provision of laboratory services for bone turnover markers. / Vasikaran, Samuel; Chubb, Paul; Schneider, H.G.

    In: Pathology, Vol. 46, No. 4, 2014, p. 267-273.

    Research output: Contribution to journalReview article

    TY - JOUR

    T1 - Towards optimising the provision of laboratory services for bone turnover markers

    AU - Vasikaran, Samuel

    AU - Chubb, Paul

    AU - Schneider, H.G.

    PY - 2014

    Y1 - 2014

    N2 - Bone turnover markers (BTMs) are either secreted by osteoblasts during bone formation or released by degradation of the collagen matrix of bone during bone resorption, and may be measured in blood or urine to provide an estimate of the rate of bone remodelling. Increased bone remodelling rate is often associated with bone loss which can result in osteoporosis; however, lack of data preclude the inclusion of BTMs in fracture risk algorithms. The changes in BTMs following therapy for osteoporosis may be useful for monitoring. Serum procollagen type I amino-terminal propeptide (s-PINP) and serum carboxy-terminal cross-linking telopeptide of type I collagen (s-βCTX) have been designated as reference standard markers of bone formation and resorption respectively in osteoporosis; further research is needed for their routine use in osteoporosis. BTMs are useful in diagnosing and monitoring Paget's disease of bone and other bone diseases associated with abnormal bone formation and/or resorption. Standardised patient preparation is required to mitigate the effect of biological variation, and appropriate sample handling and storage are important to minimise sample degradation. Significant inter-method differences exist for BTMs, and harmonisation of methods for the reference BTMs is being pursued. This will help develop universally accepted decision limits and treatment goals. Australian consensus reference intervals have been developed for some methods for s-PINP and s-βCTX © 2014 Royal College of Pathologists of Australasia.

    AB - Bone turnover markers (BTMs) are either secreted by osteoblasts during bone formation or released by degradation of the collagen matrix of bone during bone resorption, and may be measured in blood or urine to provide an estimate of the rate of bone remodelling. Increased bone remodelling rate is often associated with bone loss which can result in osteoporosis; however, lack of data preclude the inclusion of BTMs in fracture risk algorithms. The changes in BTMs following therapy for osteoporosis may be useful for monitoring. Serum procollagen type I amino-terminal propeptide (s-PINP) and serum carboxy-terminal cross-linking telopeptide of type I collagen (s-βCTX) have been designated as reference standard markers of bone formation and resorption respectively in osteoporosis; further research is needed for their routine use in osteoporosis. BTMs are useful in diagnosing and monitoring Paget's disease of bone and other bone diseases associated with abnormal bone formation and/or resorption. Standardised patient preparation is required to mitigate the effect of biological variation, and appropriate sample handling and storage are important to minimise sample degradation. Significant inter-method differences exist for BTMs, and harmonisation of methods for the reference BTMs is being pursued. This will help develop universally accepted decision limits and treatment goals. Australian consensus reference intervals have been developed for some methods for s-PINP and s-βCTX © 2014 Royal College of Pathologists of Australasia.

    U2 - 10.1097/PAT.0000000000000092

    DO - 10.1097/PAT.0000000000000092

    M3 - Review article

    VL - 46

    SP - 267

    EP - 273

    JO - Pathology

    JF - Pathology

    SN - 0031-3025

    IS - 4

    ER -